Home >News center
Henan Yinfeng passed the standard audit of intellectual property management system
2018-06-05 15:42:47

 On December 10, 2017, Henan Yinfeng Biotechnology Engineering Technology Co., Ltd. (hereinafter referred to as "Henan Yinfeng") successfully passed the standard audit of the intellectual property management system.

Henan Yinfeng's intellectual property management system was launched in June 2017. After nearly 6 months of pre-counseling, system operation, internal audit, management review and pre-audit, etc., finally see (Beijing) Certification Co., Ltd. dispatched on-site audit team to our company.

The expert review team reviewed the relevant documents and operating procedures of Henan Yinfeng Stem Cell Technology, R&D, quality, and procurement departments through reviewing the company's operating system records, face-to-face conversations, and on-site observations. In the end, the reviewing officers affirmed Henan Yinfeng's intellectual property management system and agreed that was effective and the audit can be passed.

Through this project review, Henan Company’s intellectual property management system has been completed and improved. The requirements of the “Management Standards of Enterprise Intellectual Property” have been integrated into the corporate R&D, production, and operation and management, can protected the company in a better way, and the management level of intellectual property rights of enterprises have been comprehensively improved, and have played an active role in  prevention and control of intellectual property risks and improving the research and development capabilities, production efficiency and market competitiveness. The Henan Yinfeng Intellectual Property Management System will also enhance the ability of independent innovation in enterprises, realize the scientific management and strategic application for intellectual property and effectively prevent potential risks of intellectual property management, and increase the market competitiveness to make a contribution to the stem cell industry.

 

TOP